Katie's skills lie in patent litigation in the telecommunications and pharmaceutical sectors.
In the telecommunications sector, Katie has extensive experience advising on and coordinating cross-border patent disputes (including acting on behalf of Qualcomm, HTC, ZTE, and other major device and infrastructure manufacturers), patent arbitration (including in relation to disputes over license fees for standards essential patents, and related license terms), and issues relating to standards essential and non-essential patents.
Katie's life sciences experience includes advising on patent terms extensions through supplementary protection certificates and paediatric extensions (including acting in the first UK cases challenging the interpretation of European legislation regarding paediatric extensions), on parallel import issues (including obtaining a favourable ruling from the Court of Justice of the EU on the interpretation of the Specific Mechanism), and on second medical use and indirect infringement issues.
She also regularly advises on a range of non-contentious and pre-litigation IP matters including review and selection of suitable candidate patents for assertion in licensing negotiations and patent litigation, and drafting and negotiating of licensing, settlement, and other commercial agreements.
Katie joined Hogan Lovells in 2003, and is a counsel in the London Intellectual Property, Media and Technology practice, as well as being a member of the firms Life Sciences and TMT teams. Katie is a Solicitor-Advocate with higher rights of audience in the English courts, and has experience acting in proceedings before the Intellectual Property Enterprise Court, Patents Court, Court of Appeal, and before the Court of Justice of the EU.
'European Patent Firm – Contentious'
'One of the best all-round IP groups in London? - dynamic partners supported by very able and hard-working associates'
Areas of Focus
Acting for Merck in first UK case dealing with the interpretation of European legislation regarding the Specific Mechanism for parallel imports.
Acting for ZTE in patent litigation against Ericsson relating to allegedly standards essential patents.
Acting for a leading manufacturer of innovative smartphones.
Acting for Merck and Du Pont on first UK cases challenging European legislation regarding pediatric extensions to supplementary protection certificates; won extension for Du Pont.
Acting for Qualcomm in its patent action against Nokia in relation to GPRS and EDGE mobile phone technology, and co-ordinating related patent actions across jurisdictions.
Advising one of world's leading food and beverage companies on IP aspects of business separation; various joint development arrangements; drafting and negotiating related contractual provisions.
Acting for Novartis on IP aspects of its acquisition of GSK's oncology products for an aggregate cash consideration of US$16bn.
Acting for Eli Lilly in its dispute with Actavis over Lilly's Alimta cancer treatment in relation to dextrose remission issues.
Acting for HTC in UK litigation against a non-practicing entity.
UK litigation against Nokia relating to over 30 allegedly non-essential patents asserted by Nokia in parallel German proceedings.
HTC's application for revocation of a patent for data entry systems.
Rising Star Intellectual Property
Super Lawyers London